Guest Editorial
I t is not what you know that gets you in trouble, it is what you know that is not true that gets you in trouble. If there is something that comes up concerning drug therapy that you are not sure about, you look into it further. On the other hand if you already know something then you just move straight ahead. This is what you have been taught and therefore, what you know about the dosing of oral colchicine at the first sign of an acute gouty arthritis attack:
give 0.6 to 1.2 mg every hour or 1.2 mg every 2 hours until pain is relieved or until diarrhea ensues. The total amount needed to control pain and inflammation during an at tack usually ranges from 4 to 8 mg.
If you were called upon today to dispense colchicine with these directions, based on what you know, which is based on what you were taught, and you dispensed the medication, then you would have been wrong.
On August 30, 2009 Food and Drug Administration (FDA) issued a drug safety and availability alert. It partially stated that FDA has now approved the first singleingredient oral colchicine product, Colcrys, for the treatment of familial Mediterranean fever (FMF) and acute gout flares.
First, FDA analyzed safety data for colchicine from adverse events reported to the Agency, the published literature, and companysponsored pharmacokinetic and drug interaction studies. This analysis revealed cases of fatal colchicine toxicity reported in certain patients taking standard therapeutic doses of colchicine and concomitant medications that interact with col chicine, such as clarithromycin. These reports suggest that drug interactions affecting the GI absorption and/or hepatic metabolism of colchicine play a central role in the development of colchicine toxicity.
Second, data submitted supporting the safety and efficacy of Colcrys in acute gout flares demonstrated that a substantially lower dose of colchicine was as effective as the higher dose traditionally used. Moreover, patients receiving the lower dose experienced significantly fewer adverse events compared with the higher dose.
Based on this information, FDA is highlighting important safety considerations found in the approved prescribing information to assure safe use of Colcrys.
FDA recommends: • Health care providers to not use P-glycoprotein (P-gp) or strong CYP3A4 inhibitors in patients with renal or hepatic impairment who are currently taking col chicine.
• Health care providers to consider a dose reduction or interruption of colchicine treatment in patients with normal renal and hepatic function if treatment with a P-gp or a strong CYP3A4 inhibitor is required. • Health care providers to prescribe the FDA-approved Colcrys dose for the treatment of acute gout flares: 1.2 mg followed by 0.6 mg in 1 hour (total 1.8 mg). • Health care providers to refer to Colcrys' approved prescribing information for specific dosing recommendations and additional drug interaction information. • Patients to review the Medication Guide for important safety information No more of that "0.6 to 1.2 mg every hour or 1.2 mg every 2 hours until pain is relieved or until diarrhea ensues." No more of that "4 to 8 mg per attack." The new dosage recommendation for the treatment of acute gout flares is 1.2 mg followed by 0.6 mg in 1 hour (total 1.8 mg).
The severity of the drug interaction warning is probably new information to most pharmacists.
You had to sit through hundreds of hours of lectures while in school, spend hundreds of hours in your clerkship, and keep up with your continuing education to amass a body of knowledge. You have your continued on page 936 *Editor Emeritus, Hospital Pharmacy, e-mail: neilmdavis@neilmdavis.com. 
Letter to the Editor

To Whom It May Concern:
I take extreme offense to Dennis Cada, PharmD, using Hospital Pharmacy to espouse what appears to be nothing more than an expression of his political viewpoint regarding the health care reform debate. Had Hospital Pharmacy chosen to offer an alternative viewpoint it might have been acceptable, but the fact that it did not has me wondering whether the journal's entire integrity is in question. I'm not sure what sources Dr. Cada used for this rant other than perhaps Fox News. His statement that a "single-payor, government-run system should never be considered" may be his own personal view, but does not reflect the view of myself or many of my pharmacist, physician, or other health care colleagues. His statement preceding that one that he is "not in disagreement that changes could be made within the current health care structure" belies an ignorance that is almost hard to believe. No one I know believes the current system (if one could even call it that) cannot be improved upon. A recent survey published in the New England Journal of Medicine indicates that greater than 60% of physicians support either an ex panded public or private insurance option for people less than 65 years old. Dr. Cada offers no actual data to support his viewpoint. The rest of the editorial continues with numerous points that offer no factual source. I have not read in any newspaper or scientific journal his claims that some government agency will have "real-time access to individuals' finances and bank accounts for electronic transfer of funds"; that employers will be required to enroll employees in a public option plan (joint congressional action hasn't gotten that far yet); that a 2.5% tax would be imposed on those who don't buy health insurance; that government will exclude special needs individuals; or his implication that there would be mandatory orders for ending life in selected patients. His statement that the malpractice system is the most "egregious" example of waste in our health care system simply isn't supported by objective evidence, most of which suggests that no more than 2% of our total health care dollars are spent on malpractice. Establishing evidence-based practice standards would better address the issue of practicing defensive medicine than doing away with recourse for individuals that are genuinely harmed by medical negligence.
An editorial is by definition an opinion. Generally, however, in reputable scientific journals those opinions are supported by evidence and facts that lead one to have that opinion. Dr. Cada does no such thing in this editorial. He offers no meaningful suggestions as to how he would like to see health care reformed and offers no evidence in support of such views. He has, in my view, done a grave disservice to a civil discussion regarding health care reform.
-Todd S. Davis, RPh
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continued from page 935 reference texts and computer, but all it takes is one bit of new in for -mation and a bit of your knowledge and references are no longer true. It is not what you know that gets you in trouble, it is what you know that is not true. It is not easy to be a pharmacist on the front line.
